// App-Quantinova.ai

5578.0 : Quality of life (QOL) for the treatment sequence of abiraterone acetate plus prednisone (AAP) followed by enzalutamide (ENZ) versus the opposite sequence for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized clinical trial.

Researchers

Presenter

  • Daniel J Khalaf

Principal Investigators

  • Katherine Sunderland

  • Bernhard J. Eigl

  • Daygen L. Finch

  • Conrad D. Oja

  • Joanna Vergidis

  • Muhammad Zulfiqar

  • Christian K. Kollmannsberger

  • Martin Gleave

  • Kim N. Chi

Medical Centers

  • BC Cancer - Vancouver Centre, Vancouver, BC, Canada

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Department of Medical Oncology, BC Cancer-Vancouver Centre, Vancouver, BC, Canada

  • BC Cancer Agency, Kelowna, BC, Canada

  • British Columbia Cancer Agency, Abbotsford Centre, Vancouver, BC, Canada

  • BC Cancer Agency Vancouver Island Centre, Victoria, BC, Canada

  • BC Cancer Agency, Abbotsford, BC, Canada

  • BC Cancer - Vancouver Centre, Vancouver, BC, Canada

  • Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada

  • Vancouver Prostate Centre, Vancouver, BC, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

  • Enzalutamide

  • Prednisone

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

Phase

  • NA

Study Id's

  • NCT02125357

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved